Wedbush raised the firm’s price target on Beam Therapeutics (BEAM) to $65 from $57 and keeps an Outperform rating on the shares. The firm notes the company reported earnings and announced its new liver-directed program: BEAM-304 for phenylketonuria. IND submission is expected in 2026, followed by a Phase 1/2 trial in patients with the R408W mutation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics price target raised to $75 from $74 at Canaccord
- Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
- Beam Therapeutics price target raised to $47 from $45 at BofA
- Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
- Beam Therapeutics announces $500M financing facility